Reuters
The Chinese company “Sinovac Biotec” said that a clinical trial in Brazil showed that the effectiveness of its vaccine was about 20% more than usual in a small group of patients who got two doses with a longer time difference.
read more
A spokesman for “Sinovac Biotech” said that the protection rate for 1,394 participants who received two doses of the Koronavac vaccine or a placebo vaccine within three weeks was about 70 percent.
Last week, Brazilian researchers announced that the overall effectiveness of the vaccine is 50.4 percent, based on the results of more than 9,000 volunteers, most of whom received two doses 14 days apart, as determined in the trial system.
The spokesman said that a small number of participants in the experiment received the second dose late for various reasons. He gave no details.
The difference between the two vaccine doses has become a hot topic among scientists, regulatory agencies and governments.
The relevant authorities in Britain said that the vaccine company “AstraZeneca” and the University of Oxford is more effective when the time period between the two doses is longer than the initial estimates.
Britain also decided to allow prolonging the period between the two doses of the two vaccines, “Pfizer” and “Biontech”, although the two companies say that they have no efficacy data except for a shorter time difference between the two doses.
Sinovac has not yet published the scientific results of Phase III trials of its vaccine, but it has been approved for exceptional use in countries including Brazil, Indonesia and Turkey.
Source: Reuters
Source link